Drug warning for myasthenia gravis patients

“Black Box” Warning for Cipro® (ciprofloxacin) and Avelox® (moxifloxacin)

Bayer HealthCare, manufacturers of Cipro® and Avelox®, have issued an announcement that they
have been directed by the US Food & Drug Administration (FDA) to place the following boxed warning
on the product labeling for these drugs:
Fluoroquinolones, including AVELOX®/CIPRO®, may exacerbate muscle weakness in persons
with myasthenia gravis. Avoid AVELOX®/CIPRO® in patients with known history of myasthenia
gravis (see Warnings and Precautions).

The Warnings section in the product labeling within each package of Cipro® goes on to say:
Exacerbation of Myasthenia Gravis: Fluoroquinolones, including CIPRO, have neuromuscular
blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.
Postmarketing serious adverse events, including deaths and requirements for ventilatory support,
have been associated with fluoroquinolone use in persons with myasthenia gravis. Avoid CIPRO in
patients with known history of myasthenia gravis.
The Information for Patients section in the product labeling says:
“…fluoroquinolones like CIPRO may cause worsening of myasthenia gravis symptoms, including
muscle weakness and breathing problems. Patients should call their healthcare provider right away if
they have any worsening muscle weakness or breathing problems.” (There are similar statements in
the Avelox® product labeling.)
Although worsening of muscle weakness in MG following administration of a fluoroquinolone antibiotic
was reported almost 30 years ago, this is the first time that the FDA has required that a specific
warning about this risk be placed on the labeling information for these drugs. (Another antibiotic with a
specific warning for MG is Ketek® (telithromycin), which has also been associated with sometimes
fatal worsening of MG.) The FDA action in requiring these warnings resulted from reports submitted
to their MedWatch Safety Information and Adverse Event Reporting Program. The FDA receives and
evaluates reports about possible drug-related adverse events that are voluntarily submitted to the
MedWatch program.
Submission of MedWatch reports is particularly important in identifying adverse drug reactions in rare
diseases such as MG. Reactions that are specific for rare diseases are not discovered during the
clinical trials performed to get new drugs approved because patients with such diseases are ineligible
to participate in most drug trials. Also, because these adverse reactions occur in isolated cases, and
many things can cause worsening in MG, it can take a long time for individual physicians to see
enough such reactions to recognize a pattern pointing to a specific medication. Anyone can submit a
MedWatch report - physicians, nurses, pharmacists, patients, even family members - and information
about how to submit a report and submission forms can be found on the MedWatch website
or by running an Internet search on “MedWatch.”
National Office • 355 Lexington Avenue, 15th Floor • New York, NY 10017 • Phone: (800) 541-5454 • (212) 297-2156 Fax: (212) 370-9047 • E-mail: • Web site:

Source: http://www.mg-mi.org/Cipro%20Warning.pdf


GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation E. Wespes (chair), I. Eardley, F. Giuliano, D. Hatzichristou, K. Hatzimouratidis (vice-chair), I. Moncada, A. Salonia, Y. Vardi Eur Urol 2006 May;49(5):806-15 Eur Urol 2010 May;57(5):804-14 Eur Urol 2012 Sep;62(3):543-52 ERECTILE DYSFUNCTION Definition, epidemiology and risk factors Er

The world

LA LISTA DE PROHIBICIONES 2013 ESTÁNDAR INTERNACIONAL El texto oficial de la Lista de Prohibiciones será mantenido por la AMA y será publicado en inglés y francés. En caso de discrepancia entre la versión inglesa y las traducciones, la versión inglesa publicada eprevalecerá. Esta Lista entrará en vigor el 1 de enero de 2013. Lista de Prohibiciones 2013 10 de septi

Copyright © 2014 Medical Pdf Articles